EGFR and lung adenocarcinoma: Notably, the use of first-generation EGFR-TKIs (e.g., gefitinib or erlotinib) as a first-line therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma has been associated with a higher objective response rate (ORR) and longer progression-free survival (PFS) than platinum-based doublet chemotherapy [5, 6].